 | Up a level |
Mulatero, Paolo; Wuerzner, Gregoire; Groessl, Michael; Sconfienza, Elisa; Damianaki, Aikaterini; Forestiero, Vittorio; Vogt, Bruno; Brunner, Hans; Gerlock, Teresa; Steele, Ronald; Schumacher, Christoph (2024). Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial. EClinicalMedicine, 71(102576) Elsevier 10.1016/j.eclinm.2024.102576
Mulatero, Paolo; Groessl, Michael; Vogt, Bruno; Schumacher, Christoph; Steele, Ronald Edward; Brooks, Ashley; Hossack, Stuart; Brunner, Hans-Rudolf (2023). CYP11B2 Inhibitor Dexfadrostat Phosphate Suppresses the Aldosterone-to-Renin Ratio, an Indicator of Sodium Retention, in Healthy Volunteers. British journal of clinical pharmacology, 89(8), pp. 2483-2496. Wiley-Blackwell 10.1111/bcp.15713
Januszewicz, Andrzej; Mulatero, Paolo; Dobrowolski, Piotr; Monticone, Silvia; Van der Niepen, Patricia; Sarafidis, Pantelis; Reincke, Martin; Rexhaj, Emrush; Eisenhofer, Graeme; Januszewicz, Magdalena; Kasiakogias, Alexandros; Kreutz, Reinhold; Lenders, Jacques W M; Muiesan, Maria Lorenza; Persu, Alexandre; Agabiti-Rosei, Enrico; Soria, Rodrigo; Śpiewak, Mateusz; Prejbisz, Aleksander and Messerli, Franz H (2022). Cardiac Phenotypes in Secondary Hypertension: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 80(15), pp. 1480-1497. Elsevier 10.1016/j.jacc.2022.08.714
